Leveraging Patient-Derived Explant Models & Complementary Tumor Models to Supercharge ADC Development

• Demonstrating the pros and cons of explants and other applied models in developing ADCs and dissecting their translational relevance
• Highlighting strategies to implement intact patient tumor explants to retain 3D architecture and the native microenvironment
• Building a full picture for strategic ADC development by combining data from multiple models to identify biomarkers, predict patient response and empower translation to the clinic

Speakers:

Tamar Uziel

Scientific Director, Research Fellow, Oncology Translational Research, Lead Engineering & Technical

AbbVie